Apoglyx exists to bring innovative therapies to patients. Our most advanced approach is targeting systemic inflammatory diseases like acute pancreatitis, COVID-19 and sepsis, where an overreaction of the immune system harms the body’s own organs. The company’s innovative molecules modulate cell transmembrane transport through aquaporin-9, a novel drug target. Aquaporins are channels for water to enter and leave cells, with broad importance in health and disease.
